Javier Pinilla

Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation

Jörge E. Cortes, Ronald Paquette, Moshe Talpaz et al. · Blood · 2008 · 51 citations

Medicine, Hematology, Oncology +14

A Phase I Study of INNO-406 in Patients with Advanced Philadelphia (Ph+) Chromosome-Positive Leukemias Who Are Resistant or Intolerant to Imatinib and Second Generation Tyrosine Kinase Inhibitors.

Hagop M. Kantarjian, Jörge E. Cortes, Philipp le Coutre et al. · Blood · 2007 · 29 citations

Medicine, Hematology, Oncology +12

Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy

Satu Mustjoki, Marja Ekblom, T. Petteri Arstila et al. · Blood · 2008 · 21 citations

Life Sciences, Immunology, Oncology +14

Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study

Hagop M. Kantarjian, F. Giles, Kapil N. Bhalla et al. · Journal of Clinical Oncology · 2009 · 21 citations

Medicine, Pharmacology, Pharmacotherapy +13

Targeting Drug-Resistant CML and Ph+-ALL with the Spectrum Selective Protein Kinase Inhibitor XL228.

Neil P. Shah, Corynn Kasap, Ronald Paquette et al. · Blood · 2007 · 20 citations

Medicine, Oncology, Pharmacology +12